BRIEF: WuXi XDC’s profit jumps in first half of 2025
Contract drug services provider WuXi XDC Cayman Inc. (2268.HK) on Wednesday said its revenue grew by over 60% in the first half of 2025, while its adjusted net profit surged by more than 67%. The company added its net profit grew by more than 50% during the period, which would equal 740 million yuan or more based on its 490 million yuan ($68 million) profit in the year-ago period.
This strong growth owed largely to strong downstream demand from makers of antibody-drug conjugates (ADCs); the company’s leadership in the bioconjugate drug services market; and the rapid ramp-up of its newly commissioned production lines.
Shares of WuXi rose 8.6% to HK$53.65 on Wednesday. The stock is up 73% this year.
By Lau Chi Hang
To subscribe to Bamboo Works weekly free newsletter, clickhere
Related Articles
BRIEF: Alibaba stock rallies as Ark Invest buys back in
BRIEF: Buffett sells BYD stake after 17-year holding, netting huge gain
RELATED ARTICLES
-
WuXi group wrestles with uncertainty over pharma tariffs
2268.HK -
Fortune smiles again on WuXi AppTec with profit surge
2359.HK 603259.SHG
-
BRIEF: ZX Inc. swings to profit in first half of 2025, rebrands as Tanwan
9890.HK
-
BRIEF: Meitu reports strong profit growth in first half of 2025
1357.HK
-
BRIEF: Shandong Gold profit surges in first half of 2025
1787.HK 600547.SHG
-
BRIEF: TCL Electronics’ adjusted profit rises sharply in first half of 2025
1070.HK
-
BRIEF: Strawbear Entertainment swings into the red in first half of 2025
2125.HK
